TheDigger Intelligence Unit
Drugmaker Eli Lilly has said it will open early access to a limited number of adults with severe obesity seeking its experimental weight-loss drug retatrutide, ahead of the medication’s expected regulatory approval next year, according to reporting by STAT, a US health and science news outlet.
The move follows disclosure that the company had already supplied the unapproved drug to a 79-year-old patient through the US Food and Drug Administration’s “compassionate use” pathway, which allows access to experimental treatments for people with serious conditions outside of a formal clinical trial.
Retatrutide is a once-weekly injectable that acts on three separate hormone receptors — GLP-1, GIP and glucagon — and remains in late-stage clinical trials. It is not yet approved for use in the United States or elsewhere.
Strong Trial Results Driving Demand
Interest in the drug has been fuelled by unusually strong results in Lilly’s own trials. In phase 3 data released by the company, participants on the highest dose lost an average of 25 percent of their starting body weight over 80 weeks when accounting for those who dropped out early; among only those who remained on treatment throughout, average weight loss reached 28.3 percent. By comparison, separate trials have reported roughly 15 per cent average weight loss with semaglutide (marketed as Wegovy) over 68 weeks, and close to 21 percent with tirzepatide (Zepbound) over 72 weeks. These drugs were not tested head-to-head against retatrutide, so the figures are not a direct comparison of effectiveness.
Who could qualify
Under the FDA‘s compassionate use framework, a drug may be considered for a patient outside clinical trials where no satisfactory treatment exists, the person cannot join a trial, potential benefits outweigh the risks, and providing it would not interfere with the drug’s ongoing development. Obesity specialists note this bar is typically easier to meet for immediately life-threatening conditions such as advanced cancer, since obesity’s complications, while serious, tend to develop over a longer timeframe.
Lilly has outlined its own eligibility criteria for the program: applicants must be adults with obesity resistant to standard treatment, unable to join a clinical trial, with at least two serious weight-related medical complications, and must have discussed all standard treatment options with a physician. Medical experts have noted that this last requirement is ambiguous, questioning whether patients would need to have actually attempted other treatments — including bariatric surgery — rather than simply having them discussed.
Limited Trial Access And a Formal Application Process
As of the article’s publication, only one US clinical trial for retatrutide was still recruiting participants, and it was limited to people with a high-risk liver condition rather than obesity generally — leaving most prospective patients without a trial pathway to the drug ahead of approval.
Patients cannot apply for compassionate use directly. A treating physician must submit the request to Lilly, and if the company agrees, further authorization from the FDA and an institutional review board is required. Lilly says it aims to respond within five business days of receiving the necessary medical information, though physicians interviewed by STAT described a process marked by delays and limited clarity.
Lilly has not disclosed how many applications it expects to approve, how long treatment would continue for approved patients, or who would cover the cost of related monitoring — leaving a significant gap between technical eligibility and actually receiving the drug. Some physicians have questioned whether the program will extend meaningfully beyond a small number of exceptional cases.
A Warning on Unauthorised Sources
Health experts have separately flagged the growing practice of obtaining retatrutide through compounding pharmacies or unauthorised online sellers marketing “research” versions of the drug. Selling compounded retatrutide is illegal, and such products carry risks including incorrect dosing, contamination, or the presence of entirely different active ingredients.
Source: Reporting based on Everyday Health (Becky Upham, published August 4, 2026), citing original reporting by STAT and phase 3 trial data released by Eli Lilly.
